Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial

Lancet

Volumn 370, Issue 9600, 2007, Pages 1687-1697

  Keech, AC ^a,b   Mitchell, P ^a   Summanen, PA ^c   O'Day, J ^d   Davis, TME ^e   Moffitt, MS ^a   Taskinen, M R ^f   Simes, RJ ^a,b   Tse, D ^a   Williamson, E ^a   Merrifield, A ^a   Laatikainen, LT ^f   d'Emden, MC ^g   Crimet, DC ^h   O'Connell, RL ^a   Colman, PG ^d  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^f UNIVERSITY OF HELSINKI   (Finland)

^g ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^h Laboratoires Fournier   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FENOFIBRATE; INSULIN; LIPID; METFORMIN; PLACEBO; SULFONYLUREA;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC RETINOPATHY; DISEASE COURSE; DRUG EFFECT; FEMALE; HUMAN; HYPERHOMOCYSTEINEMIA; INCIDENCE; LIPID BLOOD LEVEL; LOW LEVEL LASER THERAPY; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREATITIS; PRIORITY JOURNAL; PROLIFERATIVE RETINOPATHY; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA EDEMA; RISK REDUCTION; SIDE EFFECT; STATISTICAL ANALYSIS; VISUAL FIELD;

EID: 36049001784     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)61607-9     Document Type: Article

References (58)

1. Porta M., and Allione A. Current approaches and perspectives in the medical treatment of diabetic retinopathy. Pharmacol Ther 103 (2004) 167-177
2. Neubauer A., and Ulbig M. Laser treatment in diabetic retinopathy. Opthamologica 221 (2007) 95-102
3. UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
4. Stratton I., Kohner E., Aldington S., et al. UKPDS 50: risk factors for incidence and progression of retinopathy in type II diabetes over 6 years from diagnosis. Diabetologia 44 (2001) 156-163
5. ETDRS Group. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology 98 (1991) 766-785
6. ETDRS Group. Photocoagulation for diabetic macular edema. ETDRS report number 1. Arch Ophthalmol 103 (1985) 1796-1806
7. Aiello L. Perspectives on diabetic retinopathy. Am J Ophthalmol 136 (2003) 122-135
8. Fong D., Aiello L., Ferris F., and Klein R. Diabetic retinopathy. Diabetes Care 27 (2004) 2540-2553
9. DCCT Group. The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetic Control and Complications Trial. Diabetes 45 (1996) 1289-1298
10. UKPDS Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. BMJ 317 (1998) 703-713
11. Chew E., Klein M., Ferris F., et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Arch Ophthalmol 114 (1996) 1079-1084
12. Davis M., Fisher M., Gangnon R., et al. Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18. Invest Ophthalmol Vis Sci 39 (1998) 233-252
13. Ferris F., Chew E., and Hoogwerf B. Serum lipids and diabetic retinopathy. Diabetes Care 19 (1996) 1291-1293
14. Chowdhury T., Hopkins D., Dodson P., and Vafidis G. The role of serum lipids in exudative diabetic maculopathy: is there a place for lipid lowering therapy?. Eye 16 (2002) 689-693
15. Lyons T., Jenkins A., Zheng D., et al. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. Invest Ophthalmol Vis Sci 45 (2004) 910-918
16. Ucgun N., Yildirim Z., Kilic N., and Gursel E. The importance of serum lipids in exudative diabetic macular edema in type 2 diabetic patients. Ann NY Acad Sci 1100 (2007) 213-217
17. Miljanovic B., Glynn R., Nathan D., Manson J., and Schaumberg D. A prospective study of serum lipids and risk of diabetic macular edema in type 1 diabetes. Diabetes 53 (2004) 2883-2892
18. Dornan T., Carter R., Bron A., Turner R., and Mann J. Low density lipoprotein cholesterol: an association with the severity of diabetic retinopathy. Diabetologia 22 (1982) 167-170
19. Dodson P., and Gibson J. Long-term follow-up of and underlying medical conditions in patients with diabetic exudative maculopathy. Eye 5 (1991) 699-703
20. van Leiden H., Dekker J., Moll A., et al. Blood pressure, lipids, and obesity are associated with retinopathy: the Hoorn study. Diabetes Care 25 (2002) 1320-1325
21. Mohamed Q., Gillies M., and Wong T. Management of diabetic retinopathy: a systematic review. JAMA 298 (2007) 902-916
22. Leung H., Wang J., Rochtchina E., Wong T., Klein R., and Mitchell P. Dyslipidaemia and microvascular disease in the retina. Eye 19 (2005) 861-868
23. Zhang J., and McGwin G. Association of statin use with the risk of developing diabetic retinopathy. Arch Ophthalmol 125 (2007) 1096-1099
24. Dorne P. Exudative diabetic retinopathy. The use of clofibrate in the treatment of hard exudates using a reduced nut prolonged dosage over several years. Am J Ophthalmol 37 (1977) 393-400
25. Harrold B., Marmion V., and Gough K. A double-blind controlled trial of clofibrate in the treatment of diabetic retinopathy. Diabetes 18 (1969) 285-291
26. Rencova E., Novak J., Saic E., and Kalinova M. Objective evaluation of the success of treatment in exudative diabetic maculopathy. Cesk Oftalmol 48 (1992) 37-41 (in Czech).
27. Freyberger H., Schifferdecker E., and Schatz H. Regression of hard exudates in diabetic background retinopathy in therapy with etofibrate antilipemic agent. Med Klin 89 (1994) 594-597 (in German).
28. Cullen J., Ireland J., and Oliver M. A controlled trial of atromid therapy in exudative diabetic retinopathy. Trans Am Ophthalmol Soc 84 (1964) 281-295
29. Duncan L., Cullen J., Ireland J., Noland J., Clarke B., and Oliver M. A three year trial of atromid therapy and exudative diabetic retinopathy. Diabetes 17 (1968) 458-467
30. The FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366 (2005) 1849-1861
31. FIELD study investigators. The Fenofibrate Intervention and Event Lowering in Diabetes Study (FIELD): baseline characteristics and short-term effects of fenofibrate. J Cardiovasc Diabetol 4 (2005) 13
32. ETDRS Group. Grading diabetic retinopathy from stereoscopic color fundus photographs- an extension of the modified Airlie House classification. ETDRS report number 10. Ophthalmology 98 (1991) 786-806
33. Aldington S., Kohner E., Meurer S., Klein R., and Sjolie A. Methodology for retinal photography and assessment of diabetic retinopathy: the EURODIAB IDDM complications study. Diabetologia 38 (1995) 437-444
34. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361 (2005) -16
35. Gordon B., Chang S., Kavanagh M., et al. The effects of lipid lowering on diabetic retinopathy. Am J Ophthalmol 112 (1991) 385-391
36. Gupta A., Gupta V., Thapar S., and Bhansali A. Lipid-lowering drug atorvastatin as an adjunct in the management of dibaetic macular edema. Am J Ophthalmol 137 (2004) 675-682
37. Ozkiris A., Erkilic K., Koc A., and Mistik S. Effect of atorvastatin on ocular blood flow velocities in patients with diabetic retinopathy. Br J Ophthalmol 91 (2007) 69-73
38. Tserentsoodol N., Gordiyenko N., Pascual I., Lee J., Fliesler S., and Rodriguez I. Intraretinal lipid transport is dependent on high density lipoprotein-like particles and class B scavenger receptors. Mol Vis 12 (2006) 1319-1333
39. Patel A., and for the ADVANCE study group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370 (2007) 829-840
40. Caldwell R., Bartoli M., Behzadian M., et al. Vascular endothelial growth factor and diabetic retinopathy: role of oxidative stress. Curr Drug Targets 6 (2005) 511-524
41. Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol 280 (2001) C1358-C1366
42. Kim J., Ahn J., Kim J., et al. Fenofibrate regulates retinal endothelial cell survival through the AMPK signal transduction pathway. Exp Eye Res 84 (2007) 886-893
43. Malik J., Melenovsky V., Wichterle D., et al. Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidemia (fenofibrate versus atorvastatin trial-FAT). Cardiovasc Res 52 (2001) 290-298
44. Meleth A., Agron E., Chan C., et al. Serum inflammatory markers in diabetic retinopathy. Invest Ophthalmol Vis Sci 46 (2005) 4295-4301
45. Hirano F., Kobayashi A., and Makino I. Inhibition of TNF-alpha-induced RANTES expression in human hepatocyte-derived cells by fibrates, the hypolipidemic drugs. Int Immunopharmacol 3 (2003) 225-232
46. Rosenson R., Wolff D., Huskin A., Helenowski I., and Rademaker A. Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory reponse in subjects with hypertriglycemia and the metabolic syndrome. Diabetes Care 17 (2007) 31-55
47. Goetze S., Eilers F., Bungenstock A., et al. PPAR activators inhibit endothelial cell migration by targeting Akt. Biochem Biophys Res Comm 293 (2002) 1431-1437
48. Demircan N., Safran B., Soylu M., Ozcan A., and Sizmaz S. Determination of vitreous interleukin-1 (IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy. Eye 20 (2006) 1366-1369
49. Ryan K., McCance D., Powell L., McMahon R., and Trimble E. Fenofibrate and pioglitazone improve endothelial function and reduce arterial stiffness in obese glucose tolerant men. Atherosclerosis 194 (2007) e123-e130
50. Losada M., and Alio J. Malondialdehyde serum concentration in type 1 diabetic with and without retinopathy. Doc Ophthalmol 93 (1997) 223-229
51. Skrha J., Stulc T., Hilgertova J., Weiserova H., Kvasnicka J., and Ceska R. Effect of simvastatin and fenofibrate on endothelium in type 2 diabetes. Eur J Pharmacol 493 (2004) 183-189
52. Connor K., SanGiovanni J., Lofqvist C., et al. Increased dietary intake of {A figure is presented}-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat Med 13 (2007) 868-873
53. de Lorgeril M., Salen P., Guiraud A., Zeghichi S., Boucher F., and de Leiris J. Lipid-lowering drugs and essential omega-6 and omega-3 fatty acids in patients with coronary heart disease. Nutr Metab Cardiovasc Dis 15 (2005) 36-41
54. Cameron A., Shaw J., and Zimmet P. The metabolic syndrome: prevalence in worldwide populations. Endocrinol Metab Clin North Am 33 (2004) 351-375
55. Aiello L., Davis M., Girach, et al. Effect of ruboxistaurin in patients with diabetic macular edema: thirty-month results of the randomized PKC-DMES clinical trial. Arch Ophthalmol 125 (2007) 318-324
56. PKC-DRS study group. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial. Diabetes 54 (2005) 2188-2197
57. Aiello L., Davis M., and for the PKC-DRS2 study group. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology 113 (2006) 2221-2230
58. Chew E., Ambrosius W., Howard L., et al. Rationale design and methods of the action to control cardiovascular risk in diabetes eye study (ACCORD-EYE). Am J Cardiol 99 12A (2007) 103i-111i